BISCHOFBERGER NORBERT W

SEC source: 0001628280-26-038961 · wk-form4_1780010616.xml · derivative · entry 3

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2036-05-26

F4 · shares: The shares subject to the stock option will vest and become exercisable in full on May 27, 2027.

SEC source: 0001628280-26-038961 · wk-form4_1780010616.xml · nonDerivative · entry 1

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,333

F1 · kind: Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.

F2 · shares: The RSUs will vest in full on May 27, 2027.

SEC source: 0001415889-25-017836 · form4-06202025_040633.xml · derivative · entry 9

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 699,800 shares

Expires 2034-02-14

F8 · derivative.exercise_date: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration.

SEC source: 0001415889-25-017836 · form4-06202025_040633.xml · derivative · entry 8

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 570,868 shares

Expires 2033-02-14

F8 · derivative.exercise_date: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration.

SEC source: 0001415889-25-017836 · form4-06202025_040633.xml · derivative · entry 7

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 400,000 shares

Expires 2032-02-15

F8 · derivative.exercise_date: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration.

SEC source: 0001415889-25-017836 · form4-06202025_040633.xml · derivative · entry 6

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 297,186 shares

Expires 2030-12-09

F8 · derivative.exercise_date: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration.

SEC source: 0001415889-25-017836 · form4-06202025_040633.xml · nonDerivative · entry 5

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.57 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price").[continues to Footnote 2]

F2 · shares: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price.

F7 · ownership.nature: By Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The Irene Alisha Bischofberger Dynasty GST Non-Exempt Trust dated April 29, 2020.

SEC source: 0001415889-25-017836 · form4-06202025_040633.xml · nonDerivative · entry 4

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.57 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price").[continues to Footnote 2]

F2 · shares: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price.

F6 · ownership.nature: By Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The Irene Alisha Bischofberger Dynasty GST Exempt Trust dated April 29, 2020.

SEC source: 0001415889-25-017836 · form4-06202025_040633.xml · nonDerivative · entry 3

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.57 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price").[continues to Footnote 2]

F2 · shares: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price.

F5 · ownership.nature: By Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The David Michael Anthony Dynasty GST Non-Exempt Trust dated April 29, 2020.

SEC source: 0001415889-25-017836 · form4-06202025_040633.xml · nonDerivative · entry 2

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.57 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price").[continues to Footnote 2]

F2 · shares: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price.

F4 · ownership.nature: By the Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The David Michael Anthony Dynasty GST Exempt Trust dated April 29, 2020.

SEC source: 0001415889-25-017836 · form4-06202025_040633.xml · nonDerivative · entry 1

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.57 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price").[continues to Footnote 2]

F2 · shares: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price.

F3 · ownership.nature: By the Norbert W. & Inger A. Bischofberger Revocable Inter Vivos Trust, dtd August 29, 1994,

SEC source: 0001628280-25-030078 · wk-form4_1749255960.xml · nonDerivative · entry 2

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 10,667

F1 · kind: Transfer without consideration for tax planning purposes.

F2 · ownership.nature: The shares are held in the name of Nextquest, LLC, of which the Reporting Person is a managing member.

SEC source: 0001628280-25-030078 · wk-form4_1749255960.xml · nonDerivative · entry 1

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,333

F1 · kind: Transfer without consideration for tax planning purposes.

SEC source: 0001628280-25-028888 · wk-form4_1748906238.xml · derivative · entry 2

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2035-05-29

F3 · shares: The shares subject to the stock option will vest and become exercisable in full on May 30, 2026.

SEC source: 0001628280-25-028888 · wk-form4_1748906238.xml · nonDerivative · entry 1

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,000

F1 · kind: Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.

F2 · shares: The RSUs will vest in full on May 30, 2026.

SEC source: 0001415889-24-021754 · form4-08202024_110813.xml · derivative · entry 6

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 23,168 shares

Expires 2034-06-03

F1 · kind: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent.

F2 · kind: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding.

F4 · price: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof.

F5 · derivative.exercise_date: The Option will vest in full on the earlier of (a) June 04, 2025 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date.

SEC source: 0001415889-24-021754 · form4-08202024_110813.xml · derivative · entry 5

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,535 shares

Expires 2033-05-31

F1 · kind: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent.

F2 · kind: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding.

F4 · price: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof.

F3 · derivative.exercise_date: The Company Stock Option ("Option") is fully vested.

SEC source: 0001415889-24-021754 · form4-08202024_110813.xml · derivative · entry 4

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 17,550 shares

Expires 2032-06-08

F1 · kind: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent.

F2 · kind: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding.

F4 · price: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof.

F3 · derivative.exercise_date: The Company Stock Option ("Option") is fully vested.

SEC source: 0001415889-24-021754 · form4-08202024_110813.xml · derivative · entry 3

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,888 shares

Expires 2031-06-16

F1 · kind: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent.

F2 · kind: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding.

F4 · price: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof.

F3 · derivative.exercise_date: The Company Stock Option ("Option") is fully vested.

SEC source: 0001415889-24-021754 · form4-08202024_110813.xml · derivative · entry 2

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,000 shares

Expires 2030-06-18

F1 · kind: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent.

F2 · kind: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding.

F4 · price: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof.

F3 · derivative.exercise_date: The Company Stock Option ("Option") is fully vested.

SEC source: 0001415889-24-021754 · form4-08202024_110813.xml · derivative · entry 1

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 24,000 shares

Expires 2029-06-26

F1 · kind: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent.

F2 · kind: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding.

F4 · price: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof.

F3 · derivative.exercise_date: The Company Stock Option ("Option") is fully vested.

SEC source: 0001415889-24-018703 · form4-07022024_120728.xml · nonDerivative · entry 2

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 10,802,138

F4 · price: The weighted average purchase price for the transaction reported was $1.2457 and the range of prices were between $1.18 and $1.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

F3 · ownership.nature: By the Revocable Inter Vivos Trust.

SEC source: 0001415889-24-018703 · form4-07022024_120728.xml · nonDerivative · entry 1

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 10,597,468

F1 · price: The weighted average purchase price for the transaction reported was $1.1655 and the range of prices were between $0.9899 and $1.20. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

F2 · balance_after: Includes 2,811,004 shares previously held directly by the Reporting Person which were transferred to Norbert W. & Inger A. Bischofberger Revocable Inter Vivos Trust, dtd August 29, 1994 (the "Revocable Inter Vivos Trust") and are now owned indirectly.

F3 · ownership.nature: By the Revocable Inter Vivos Trust.

SEC source: 0001415889-24-016563 · form4-06122024_110650.xml · nonDerivative · entry 3

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 7,375,616

F4 · price: The weighted average purchase price for the transaction reported was $1.2428 and the range of prices were between $1.13 and $1.30. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

F2 · ownership.nature: By the Norbert W. & Inger A. Bischofberger Revocable Inter Vivos Trust, dtd August 29, 1994.

SEC source: 0001415889-24-016563 · form4-06122024_110650.xml · nonDerivative · entry 2

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 6,493,703

F3 · price: The weighted average purchase price for the transaction reported was $1.0944, and the range of prices were between $0.9299 and $1.15. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided

F2 · ownership.nature: By the Norbert W. & Inger A. Bischofberger Revocable Inter Vivos Trust, dtd August 29, 1994.

SEC source: 0001415889-24-016563 · form4-06122024_110650.xml · nonDerivative · entry 1

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 5,749,395

F1 · price: The weighted average purchase price for the transaction reported was $0.8764 and the range of prices were between $0.7392 and $0.95. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

F2 · ownership.nature: By the Norbert W. & Inger A. Bischofberger Revocable Inter Vivos Trust, dtd August 29, 1994.

SEC source: 0001415889-24-015664 · form4-06052024_110622.xml · derivative · entry 1

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,168

Underlying: Common Stock · 23,168 shares

Expires 2034-06-03

F1 · derivative.exercise_date: The option will vest in full on the earlier of (a) June 04, 2025 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date.

SEC source: 0001628280-24-025997 · wk-form4_1717180847.xml · derivative · entry 3

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2034-05-28

F2 · derivative.exercise_date: Shares subject to the stock option vest and become exercisable on the earlier of (i) May 29, 2025, or (i) the date of the Company's next annual meeting of stockholders.

SEC source: 0001628280-24-025997 · wk-form4_1717180847.xml · derivative · entry 2

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2034-05-28

F1 · derivative.exercise_date: 1/3 of the shares subject to the stock option vest and become exercisable on May 29, 2025, and the remaining shares vest in 24 equal monthly installments thereafter.

SEC source: 0001628280-24-025997 · wk-form4_1717180847.xml · nonDerivative · entry 1

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,000

SEC source: 0001415889-24-004262 · form4-02172024_010220.xml · derivative · entry 7

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 699,800

Underlying: Common Stock · 699,800 shares

Expires 2034-02-14

F6 · derivative.exercise_date: The shares vest in 48 equal monthly installments beginning on February 15, 2024.

SEC source: 0001415889-24-004262 · form4-02172024_010220.xml · nonDerivative · entry 1

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,811,004

SEC source: 0001209191-23-055826 · doc4.xml · nonDerivative · entry 3

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,540,665

F3 · price: The weighted average purchase price for the transaction reported was $1.084, and the range of prices were between $1.04 and $1.12. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001209191-23-055826 · doc4.xml · nonDerivative · entry 2

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,442,730

F2 · price: The weighted average purchase price for the transaction reported was $0.9965, and the range of prices were between $0.90 and $1.05. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001209191-23-055826 · doc4.xml · nonDerivative · entry 1

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,180,297

F1 · price: The weighted average purchase price for the transaction reported was $0.8045, and the range of prices were between $0.765 and $0.90. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001209191-23-034044 · doc4.xml · derivative · entry 1

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,535

Underlying: Common Stock · 12,535 shares

Expires 2033-05-31

F1 · derivative.exercise_date: The option will vest in full on the earlier of (a) June 1, 2024 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date.

SEC source: 0001209191-23-010559 · doc4.xml · derivative · entry 7

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 570,868

Underlying: Common Stock · 570,868 shares

Expires 2033-02-14

F6 · derivative.exercise_date: 1/48th of the shares subject to the option vest in equal monthly installments over a four year period following the date of grant.

SEC source: 0001209191-22-036112 · doc4.xml · derivative · entry 1

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,550

Underlying: Common Stock · 17,550 shares

Expires 2032-06-07

F1 · derivative.exercise_date: The option will vest in full on the earlier of (a) June 8, 2023 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date.

SEC source: 0001209191-22-030688 · doc4.xml · nonDerivative · entry 3

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 809,609

F3 · price: The weighted average purchase price for the transaction reported was $3.7817, and the range of prices were between $3.54 and $4.00. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001209191-22-030688 · doc4.xml · nonDerivative · entry 2

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 509,609

F2 · price: The weighted average purchase price for the transaction reported was $3.7248, and the range of prices were between $3.60 and $4.00. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001209191-22-030688 · doc4.xml · nonDerivative · entry 1

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 303,411

F1 · price: The weighted average purchase price for the transaction reported was $3.8329, and the range of prices were between $3.70 and $3.95. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001209191-22-010910 · doc4.xml · derivative · entry 7

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 400,000

Underlying: Common Stock · 400,000 shares

Expires 2032-02-15

F6 · derivative.exercise_date: 1/48th of the shares subject to the option vest in equal monthly installments over a four year period following the date of grant.

SEC source: 0001209191-21-068594 · doc4.xml · nonDerivative · entry 1

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 212,480

F1 · price: The weighted average purchase price for the transaction reported was $12.085, and the range of prices were between $11.83 and $12.17. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001209191-21-041667 · doc4.xml · derivative · entry 1

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2031-06-16

F1 · derivative.exercise_date: The option will vest in full on the earlier of (a) June 16, 2022 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date.

SEC source: 0001209191-22-026224 · doc4a.xml · derivative · entry 1

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,888

Underlying: Common Stock · 9,888 shares

Expires 2031-06-16

F1 · shares: This Form 4 is being amended to reflect the amount actually granted, as the originally reported share number was in error.

F2 · derivative.exercise_date: The option will vest in full on the earlier of (a) June 16, 2022 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date.

SEC source: 0001209191-20-062953 · doc4.xml · derivative · entry 7

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 297,186

Underlying: Common Stock · 297,186 shares

Expires 2030-12-09

F6 · derivative.exercise_date: 1/48th of the shares subject to the option vest in equal monthly installments over a four year period following the date of grant.

SEC source: 0001209191-20-062953 · doc4.xml · nonDerivative · entry 1

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 198,124

SEC source: 0001209191-20-055030 · doc4.xml · derivative · entry 15

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 263,750 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · price: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F6 · ownership.nature: By Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The Irene Alisha Bischofberger Dynasty GST Non-Exempt Trust dated April 29, 2020.

SEC source: 0001209191-20-055030 · doc4.xml · derivative · entry 14

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 263,750 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · price: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F5 · ownership.nature: By Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The Irene Alisha Bischofberger Dynasty GST Exempt Trust dated April 29, 2020.

SEC source: 0001209191-20-055030 · doc4.xml · derivative · entry 13

BISCHOFBERGER NORBERT W · CIK 0001190273 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 263,750 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · price: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F4 · ownership.nature: By Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The David Michael Anthony Dynasty GST Non-Exempt Trust dated April 29, 2020.